Imugene Ltd - ESG Rating & Company Profile powered by AI
This page displays a zero-cost E,S&G analysis for Imugene Ltd. The report of Imugene Ltd was prepared by All Street Sevva using advanced artificial intelligence. This assessment of Imugene Ltd incorporates data points from across the web and also from public documents by Imugene Ltd.
Imugene Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 36 | Repligen Corp | 8.1 | High |
| 36 | Zealand Pharma A/S | 8.1 | High |
| 55 | Imugene Ltd | 8.0 | High |
| 55 | Abbott India Ltd | 8.0 | High |
| 55 | Amrutanjan Health Care Ltd | 8.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Imugene Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Imugene Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Imugene Ltd report the average age of the workforce?
Sign up for free to unlockDoes Imugene Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Imugene Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Imugene Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Imugene Ltd offer flexible work?
Sign up for free to unlockDoes Imugene Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Imugene Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Imugene Ltd conduct supply chain audits?
Sign up for free to unlockDoes Imugene Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Imugene Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Imugene Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Imugene Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Imugene Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Imugene Ltd disclose water use targets?
Sign up for free to unlockDoes Imugene Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Imugene Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Imugene Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Imugene Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Imugene Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Imugene Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Imugene Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Imugene Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Imugene Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Imugene Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Imugene Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Imugene Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Imugene Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Imugene Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Imugene Ltd disclose its waste policy?
Sign up for free to unlockDoes Imugene Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Imugene Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Imugene Ltd disclose energy use targets?
Sign up for free to unlockDoes Imugene Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Imugene Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Imugene Ltd
These potential risks are based on the size, segment and geographies of the company.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.